D-0584-2025 Class II Ongoing

Recalled by Merck & Co. Inc — Rahway, NJ

FDA drug recall D-0584-2025 was initiated by Merck & Co. Inc on July 21, 2025 and is designated Class II. Reason for recall: Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep. The recall status is ongoing. Affected quantity: 51,320 cartons.

Recall Details

Product Type
Drugs
Report Date
August 20, 2025
Initiation Date
July 21, 2025
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
51,320 cartons

Product Description

Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label)

Reason for Recall

Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

Distribution Pattern

Nationwide in the USA and PR.

Code Information

Lots 2090019 and 2123744, Exp. 4/30/2027